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2Abstract
Purpose: We investigated whether microRNA expression data from
glioblastoma could be used to produce a profile that defines a bevacizumab
responsive group of patients.
Patients and Methods: TCGA microRNA expression data from tumors
resected at first diagnosis of glioblastoma in patients treated with
bevacizumab at any time during the course of their disease were randomly
separated into training (n=50) and test (n=37) groups for model generation.
MicroRNA-seq data for 51 patients whose treatment included bevacizumab in
the BELOB trial were used as an independent validation cohort.
Results: Using penalized regression we identified 8 microRNAs as potential
predictors of overall survival in the training set. We dichotomized the response
score based on the most prognostic minimum of a density plot of the
response scores (log-rank HR=0.16, p=1.2e-5) and validated the profile in the
test cohort (one-sided log-rank HR=0.34, p=0.026). Analysis of the profile
using all samples in the TCGA glioblastoma dataset, regardless of treatment
received, (n=473) showed that the prediction of patient benefit was not
significant (HR=0.84, p=0.083) suggesting the profile is specific to
bevacizumab. Further independent validation of our microRNA profile in RNA-
seq data from patients treated with bevacizumab (alone or in combination with
CCNU) at glioblastoma recurrence in the BELOB trial confirmed that our
microRNA profile predicted patient benefit from bevacizumab (HR=0.59,
p=0.043).
Conclusion: We have identified and validated an 8-microRNA profile that
predicts overall survival in patients with glioblastoma treated with
3bevacizumab. This may be useful for identifying patients who are likely to
benefit from this agent.
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41. Introduction
Bevacizumab (BEV) is an anti-angiogenic monoclonal antibody that acts by
slowing the growth of new blood vessels in tumors through inhibition of
VEGFA (vascular endothelial growth factor A) (Glade-Bender et al., 2003). In
glioblastoma, two prospective, randomized, placebo controlled clinical trials,
AVAglio and RTOG 0825 have been performed to assess whether BEV
improves survival in patients with newly diagnosed glioblastoma (Chinot et al.,
2014; Gilbert et al., 2014). Both studies reported improved progression-free
survival (PFS) but no overall survival (OS) benefit. Despite these results there
is anecdotal evidence, and some evidence from observation of tails of Kaplan
Meier survival curves, that certain patients may benefit from BEV treatment.
Identification of these patients is an unmet need (Field et al., 2014; Prados et
al., 2015).
Prediction of benefit from BEV in glioblastoma patients has been attempted
previously. Colman et al developed a prognostic signature for glioblastoma
(all treatments) which was based on expression of genes associated with
mesenchymal differentiation and angiogenesis (Colman et al., 2010). This
was then assessed using tumor samples from the RTOG 0825 patients3. The
results did not show the expected association between worse OS and PFS
with the mesenchymal subtype.
A smaller phase II trial (the BELOB trial) in the Netherlands assessed BEV or
CCNU mono-or combination therapy in recurrent glioblastoma, with a primary
endpoint of OS (Taal et al., 2014). However, survival benefit in glioblastoma
could not be confirmed in the phase III EORTC 26101 trial (Wick et al., 2015).
When patients from the BELOB trial were assigned to molecular subtypes
5results showed that the EGFR amplified, classical glioblastoma subtype
responded well to the combination therapy and the mesenchymal subtype
showed a poor response to combination therapy. It should be noted that these
data included only 28 patients in the mesenchymal single agent BEV group,
and they are not yet fully published (Eraslan et al., 2014). Overall, these, and
other data may suggest that anti-angiogenic therapy resistance is associated
with the mesenchymal transition, and that tumors with more infiltrative
phenotypes are more resistant to these drugs (Piao et al., 2013; 2012).
Retrospective analysis of the AVAglio trial showed patients with IDH wild-type
proneural tumors had improved OS when treated with BEV first-line, and
these are the most encouraging data linking tumor sub-type to outcome thus
far (Omuro et al., 2014).
Further analysis of translational data from the AVAglio trial suggested that
neither VEGFA or VEGFR2 (vascular endothelial growth factor receptor 2) are
predictive or prognostic biomarkers in the context of BEV treatment, although
a VEGFA SNP rs2010963 is associated with vascular toxicity (Di Stefano et
al., 2014; Field et al., 2014). Plasma levels of MMP2 (matrix
metalloproteinase 2) have been shown to be associated with response and
survival in BEV-treated patients (single agent therapy) in a study by the
Chinot lab (Tabouret et al., 2014).
MicroRNAs have not been studied as predictive indicators for BEV response
to date. Their stability in clinical samples and role in glioma biology suggest
they represent prime candidates for use in predictive signatures/profiles (Hall
et al., 2012; Hayes et al., 2014).
6In this study, we have attempted to identify a prognostic microRNA profile in
BEV treated patients using OS as an endpoint. Our results show that an 8-
microRNA profile can define patients treated with BEV who have a better
prognosis.
2. Materials and methods
2.1. TCGA clinical information and expression data
Level 3 Agilent microRNA 8x15k microarray expression data plus clinical and
treatment information for 563 glioblastoma samples, 90 of which were from
patients treated with BEV used either as an adjuvant with first-line treatment,
at progression or recurrence, were downloaded from TCGA (Cancer Genome
Atlas Research Network, 2008). Patients had been treated using varying
numbers of 2-3 week cycles of BEV therefore treatment time was determined
as the date from the start of treatment to the date of the end of treatment.
Samples were taken at diagnosis and OS was measured from the date of
diagnosis, regardless of timing of BEV treatment (however timing of treatment
was analyzed as a variable in a separate multivariable analysis). Three
patients were removed due to lack of start date information, resulting in a total
of 87 patients. These were randomly split into test and training set groups of
50 and 37 patients respectively (Table 1). These numbers were chosen to
maximize power in generation of the model, whilst allowing a sufficient
validation cohort for testing of the model.
2.2. Generation of a risk algorithm for OS in bevacizumab-treated
glioblastoma patients using microRNAs
7The training set samples were assessed using LASSO penalized regression
(Tibshirani, 1996) with leave-one-out cross-validation using R software
(v2.15.1) and the Penalized package (Goeman, 2010). This produced 8
microRNAs with non-zero coefficients.
A response score was generated using the sum of microRNA expression
values weighted by the coefficients from the LASSO regression.
This was: E_miR-n = expression of microRNA n.
Response score = 0.055E_miR-124a + 0.309E_miR-202 + -0.184E_miR-204
+ 0.170E_miR-222 + -0.194E_miR-363 + -0.025E_miR-630 + -0.322E_miR-
663 + 0.161E_miR-7
The response score was applied to all samples in the training set. The most
prognostic cut-off was chosen based on log-rank tests at each minimum value
on a density plot. The rationale behind this is that biologically it is assumed
that patients either show some benefit to the treatment or not. The training set
samples were then separated into responders and non-responders using this
cut-off. A Cox regression model incorporating age and the log-rank test were
used to assess OS of the two groups in the training set. 200 permutations of a
50-patient training set from the 87 original patients were used as input to
LASSO to determine model differences with different patients. The response
score was also assessed as a predictor of PFS. A statistical significance
threshold of p=0.05 was used throughout, with two-tailed log rank tests for the
training set and one-tailed tests for all validations. The length of treatment
time was tested for correlation with the survival time in both responder and
8non-responder groups. Fisher’s exact test was also performed on the
responder groups for the molecular subtype, treatment regimen and
histological features.
2.3. Validation of the response score in the test set
The response score was calculated with the above algorithm using the
microRNA expression values for the 37 test set samples. The defined cut-off
from the training set of a response score of 0 was used to separate the test
set into two groups of responders and non-responders. A Cox regression
model incorporating age and the log-rank test were used to assess OS of the
responder groups. The length of treatment time was assessed for correlation
with survival time in both responder and non-responder groups. Multivariate
analysis of other prognostic indicators assessed in the trial was performed to
determine whether the responder groups are independent prognosis
predictors.
2.4. Testing of the algorithm across all treatment types
The response score was applied to all 473 patients in the TCGA (treated with
various treatment regimens not including BEV) (Table S1). This cohort was
split into two responder groups based on the response score cut-off of 0 and
the two groups were assessed by Cox regression and log-rank test.
2.5. Validation of the profile using BELOB trial data
3DWLHQWVZHUHHOLJLEOHIRUWKH%(/2%WULDOLIWKH\ZHUH\HDUVDQGKDGD
first recurrence of glioblastoma after temozolomide and radiotherapy
9treatment. Details of the study have been described previously (Taal et al.,
2014). Total RNA extraction, purification, and quantification from formalin-
fixed and formalin-fixed paraffin-embedded (FFPE) material were reported
previously (Gravendeel et al., 2011). 500 ng RNA was used for sequencing on
an Illumina TruSeq and ~35-40 million 40 base paired end-reads were
generated per sample. RNA-seq (n=96) was run by Expression Analysis
(Durham, NC). Gene expression levels (Ref-seq genes) were extracted from
the RNA-seq data using featureCounts (Liao et al., 2014), after alignment on
hg19 with Tophat2 (Trapnell et al., 2009) of clipped/trimmed reads as
provided by the manufacturer. The response score was calculated using read
per million counts and the cut-off value was defined by using the minimum
value of a density plot of the response scores.
3. Results
3.1. An 8-microRNA profile generated from the training set predicts
prognosis in bevacizumab treated patients
Using the LASSO method, 8 microRNAs were identified with non-zero
regression coefficients in our training dataset of 50 glioblastomas. A response
score was created using the algorithm stated in methods. The response score
was then plotted as a density plot (Fig 1). The response score itself showed a
normal distribution (Fig S1) and therefore the minimum values of a density
plot at a bandwidth of 0.009 were used as a guide for determining a cut-off.
The response score value at each minimum of the density plot was
determined and a log-rank test was performed with this value as a cut-off to
determine an optimal cut-off for dichotomization. The minimum density that
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occurred around a response score of 0 showed the highest significance with
the best hazard ratio, and so a response score of 0 was chosen for the cut-off
(Fig 2A, Table S2). This cut-off is justified because the expression data are
quantile normalized, and therefore a cut-off of 0 represents the expression of
each of the microRNAs in the signature at median survival of all patients. The
median survival time of the responder group defined in this way was 22
months and the median of the non-responder group was 12 months. A log
rank test performed on 200 permutations of the 50-patient training set was
significant for predicting altered survival in 100% of tests with p<0.05 and in
96.5% of tests with p<0.005.
Spearman’s correlation of duration of BEV treatment with survival time
showed that the responders showed a correlation (correlation
coefficient=0.48, p=0.01) whereas the non-responders did not (correlation
coefficient=0.36, p=0.12). Multivariable Cox regression of the responder group
and age showed the responder group to be an independent predictor of
survival irrespective of age (group HR=0.11, CI=0.04-0.29, p=5.4e-6, age
HR=1.03, CI=1.00-1.06 p=3.3e-2).
3.2. Assessment of the profile in the test group of 37 patients
Response scores were calculated for the 37 test set patients using a cut-off of
0 to separate the patients into responder and non-responder groups. This
produced a group of 18 responders, with a median survival 21 months and a
group of 19 non-responders with a median survival of 15 months. A one-sided
log rank test showed that the responders survived significantly longer than the
non-responders (HR=0.34, CI=0.11-1.01, p=0.026, Fig. 2B). Multivariable
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Cox regression with age confirmed that the responder group was a prognostic
factor (HR=0.33, CI=0.11-0.99, p=0.049) independent of patient age.
3.3. Testing of the profile across all the glioblastoma patients in the
TCGA database, independent of treatment
To test whether our profile is predictive of patient outcome in general or
specific to BEV, we calculated the response score for all 473 glioblastoma
patients in the TCGA database. These were treated with various drugs and
regimes not including those treated with BEV (Table S1). This identified 256
patients in the responder group (median survival 9.25 months) and 217 in the
non-responder group (median survival 7.55 months). A two-sided log rank
test between the responder groups showed this profile is not prognostic for
OS (HR=0.84, CI=0.68-1.02, p=0.083, Fig 3). This indicates the profile is
predicting benefit from BEV specifically.
3.4. Characterization of the responder groups defined by the profile
We determined the proportions of each molecular glioblastoma subtype in the
responder and non-responder groups of the combined test and training sets.
Analysis using Fisher’s exact test showed that there were significantly fewer
mesenchymal type tumors in the responder group (p=0.041). The other
subtypes did not show any significant difference between the responder and
non-responder groups (classical glioblastoma p-value=0.15, neural
glioblastoma p-value=0.56, proneural G-CIMP glioblastoma p-value=1.00,
proneural non-G-CIMP glioblastoma p=1.00). Multivariable Cox regression
using the microRNA profile and subtype (as the only variables in the model)
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showed that the microRNA profile was independent of subtype using a two-
tailed test in the training set (HR= 0.13, 95% CI=0.05-0.37, p=1.1e-4) and
using a one-tailed test in the test set (HR= 0.28, 95% CI=0.07-1.15, p=0.04).
Previous data have suggested that molecular subtype may be predictive of
benefit from BEV (Eraslan et al., 2014); however, the microRNA-based BEV
response profile we have identified here has more predictive power than the
molecular glioblastoma subtypes when directly tested.
The cohort of BEV treated patients includes different treatment start points
during the course of a patient’s disease. There was no significant difference in
any treatment regime between the responder groups when tested with
Fisher’s exact test (adjuvant p-value=0.79, progression p-value= 1.00,
recurrence p-value=0.45). Multivariable Cox regression using the microRNA
profile and subtype showed that the microRNA profile was independent of
treatment time using a two-tailed test in the training set (HR=0.12, 95%
CI=0.04-0.32, p=2.4e-5). A similar trend was observed in the test set (HR=
0.44, 95% CI=0.14-1.31, p=0.07) (although treatment time data were available
for only 70% of patients in the test set cohort).
3.5. Ability of the profile to predict progression free survival
We tested whether the 8-microRNA profile predicts PFS using Cox regression
in both the test and training sets. As the cut-off for PFS may be different than
that for OS, the score was also assessed for ability to predict survival. The
training set showed that decreasing response score predicts PFS (HR=0.37,
95% CI=1.42-5.03, p=0.0024) and the dichotomized responder groups have
significantly different PFS by log-rank test (HR=0.48, 95% CI=0.25-0.93,
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p=0.029). In the test set, decreasing response score predicted PFS (HR=0.44,
95% CI=1.02-5.04, p=0.045) but the dichotomized responder groups did not
(HR=0.58, 95% CI=0.29-1.13, p=0.11). This may be because of the small size
of the test set.
3.6. Validation of the profile using data from the BELOB trial
To independently validate the profile we calculated response scores for each
of the patients in the BELOB trial using the microRNA algorithm. This was
done using aligned reads from RNA-seq data and was performed blind, with
no knowledge of clinical data. An identical cut-off to that in the training set was
not possible, because this used microRNA reads from an RNA-seq dataset
and could not be normalized in the same way as the microarray data from the
TCGA. The response score was plotted on a density plot and the minimum
value of this density plot used as a cut-off to generate two response groups
(Fig 4A-B). One-tailed log-rank tests in all arms of the trial, and in just the
arms that included bevacizumab as a treatment (either monotherapy or in
combination with CCNU) are shown in Fig 4 and patient OS data from the
BELOB trial are shown in Fig S2. In the BEV treated arms, the responder
groups were significantly associated with survival (HR 0.59, 95% CI 0.32-
1.09, p= 0.043) validating that the profile delineates patient groups with
differing benefit from BEV. Log rank test of the predicted responders from the
BEV arms with the predicted non-responders from the CCNU showed no
significance (HR 1.12, 95% CI 0.51-2.49, p=0.36, Fig S3), which may suggest
that the profile specifically defines a group of patients who do not benefit
when treated with BEV. These results indicate that even the patient responder
14
group treated with BEV show no more improvement in survival than those
from the non-responder group treated with CCNU.
Clinico-pathological markers including age, gender, MGMT methylation
status, IDH1 mutation status, were assessed by univariate and multivariate
analysis in the whole trial and this showed that the responder groups defined
by the profile were independently associated with survival (Table 2).
4. Discussion
This study has identified an 8-microRNA profile that is associated with
prognosis in BEV-treated glioma patients. The profile, with further validation,
could be used as an indicator at diagnosis to determine whether a patient will
benefit from BEV, at any time during their disease. This profile is preferable to
previously published signatures/profiles because it uses only 8 predictors,
which can easily be assayed in a clinical setting, using stable genetic markers
(microRNAs) and has better prediction power than other factors such as
MGMT promoter methylation status, IDH mutation and molecular subtype.
Sandmann et al reported that proneural IDH- wild-type tumors might respond
to first line BEV treatment (Sandmann et al., 2015). We did not find that there
were more proneural non-G-CIMP patients in the responder group. This may
be because this group is not highly represented in our data. There were fewer
patients with tumors of mesenchymal molecular glioblastoma subtype in the
responder category although 38% of mesenchymal tumors still stratified to the
responder group, which indicates that the profile is not simply predicting a
mesenchymal subtype.
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If the microRNAs in the profile are associated with BEV response it is
assumed they have a role in angiogenesis. The microRNAs that have a
positive weight in the profile (miR-7, miR-124a, miR-202 and miR-222), and
therefore are lower in responders, are likely to be anti-angiogenic. This is
because responders should have more angiogenic tumors than non-
responders. The converse is also likely to be true for the negatively weighted
microRNAs (miR-204, miR-663, miR-630 and miR-363).
Of the eight microRNAs identified in the profile, seven are reported in the
literature to be involved in angiogenesis. Of the positively-weighted
microRNAs, miR-124a has been shown to transcriptionally decrease VEGF
through RAS signaling (Shi et al., 2014) and miR-222 is considered one of
three most important anti-angiogenic microRNAs in coronary artery disease
(Zhang et al., 2011). Overexpression of miR-7 in a neuroblastoma mouse
model significantly reduced angiogenesis and in endothelial cell lines miR-7
overexpression decreased tube formation and sprouting (Babae et al., 2014).
Of the microRNAs that were negatively weighted, miR-363 and miR-663 are
reported to improve endothelial cell angiogenesis and endothelial interaction
with hematopoietic precursors(Costa et al., 2013) and miR-663 indirectly
increases VEGF and promotes angiogenesis (Afonyushkin et al., 2012). The
reports on these microRNAs are concordant with their effect in the profile.
However, miR-204 and miR-630 show anti-angiogenic properties and are
negatively weighted microRNAs; miR-204 directly decreases VEGF and also
targets angiopoietin-1 (Kather et al., 2014; Zhao et al., 2014), and miR-630
has been shown to be induced by the anti-angiogenic protein angiopoietin-like
protein 1 (Kuo et al., 2013). These unexplained functions of certain
16
microRNAs in the signature are likely reflective of the complex biology
involved in the response of a patient and their tumor to BEV.
In summary, we have defined a promising approach to predicting response to
BEV in GBM patients and further studies are warranted to test this profile
further, in larger cohorts using clinically relevant assays.
Figures and tables
Table 1. Summary of data from the test and training set cohorts. Samples
from TCGA were randomly split into training and test sets of 50 and 37
patients respectively. The test set has a marginally poorer prognosis and KPS
and, on average, 28.5 days shorter treatment time for BEV. Additionally, 22%
of test set patients were treated with BEV as an adjuvant treatment, whereas
only 16% of patients in the training set were treated as an adjuvant treatment.
Days to death are recorded where possible, and where the patient was living
at the end of the data collection, days to last follow-up were used.
Figure 1. Density plot of the response scores to determine a cut-off for
dichotomization. The response score, calculated according to the microRNA
profile algorithm was illustrated as a density plot (bandwidth 0.009). This
shows the fraction of patients with scores at each value on the X-axis and was
used to determine whether a natural cut-off of the response score could be
ascertained for dichotomization of the score into two groups of responders
and non-responders. As multiple minima were identified from the density plot,
the optimal minimum was determined by assessing prognostic ability. Each
minimum value was used as a cut-off to define two ‘response’ groups. These
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two groups were then assessed for differences in survival using the log rank
test. The hazard ratio and p-value at each minimum are shown on the plot.
The most significant association with survival occurred when a cut-off score of
0 was used which corresponds to the baseline hazard determined by the
microRNAs.
Figure 2. MicroRNA expression and patient survival in the responder
and non-responder groups in the test and training sets. The responder
and non-responder groups were calculated using the microRNA profile and
split into two responder groups using a cut-off score of 0. (A) A heat map and
survival curve of microRNA expression of the 8 profile microRNAs and
survival of the responder and non-responder groups in the training set.
Negative microRNAs are those that are higher in samples from patients with
poorer survival and conversely, positive microRNAs are those that are lower
in patients with poorer survival. The accompanying survival curve confirms
that patients who stratified to the responder group using the profile had a
better outcome than those stratified to the non-responder group. (B) A heat
map and survival curve of microRNA expression of the 8 profile microRNAs
and survival of the responder and non-responder groups in the test set. A
one-tailed log-rank test showed that patients stratified to the responder group
in the test set had a better outcome than those in the non-responder group, as
shown in the accompanying survival curve.
Figure 3. The survival of the profile-defined responder and non-
responder groups when calculated for all glioblastoma patients in the
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TCGA. In order to determine whether the profile-based definitions of
responder and non-responder groups are specific to patients treated with
BEV, the response score was calculated and a cut-off score of 0 was used to
test all the patients in the TCGA, regardless of their treatment (not including
those patients treated with BEV). The profile-defined responder groups were
not associated with prognosis (HR BEV-treated training set = 0.16, HR bev-
treated test set 0.34, HR all treatments = 0.84). This suggests that the profile
predicts prognosis more strongly in BEV treated glioblastoma.
Figure 4. Survival curves for the profile-defined responder and non-
responder groups in different arms of the BELOB trial. In order to validate
the profile, the microRNA profile response score was calculated for patients in
the BELOB trial who were treated with BEV (either as monotherapy or in
combination with CCNU). (A) A density plot at bandwidth 0.009 of the
response scores showed one minimum at a response score of 1.71 and this
was used as a cut-off to dichotomize. The calculation was performed blind,
with the investigator having no knowledge of the clinical details of the patients.
(B) MicroRNA expression of the response groups in the validation group.
Negative microRNAs are those that are higher in samples from patients with
poorer survival and conversely, positive microRNAs are those that are lower
in patients with poorer survival. MiR-202 sequences were not detected in this
group but microRNA reads are of low abundance in RNA-seq data and miR-
202 may therefore be expressed in these samples. (C) Survival of responder
and non-responder groups in all treatment arms from the BELOB trial (n=73).
(D) Survival of responder and non-responder groups in the arms that included
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BEV as a treatment (monotherapy or in combination with CCNU, n=51). The
responder groups from other arms in the trial have been included for clarity.
Table 2. Univariate and multivariate analysis of parameters from the
validation group. Using univariate analysis, the microRNA profile, Karnofsky
performance score (KPS), MGMT methylation (MGMT) were also associated
with survival in the trial cohort. Four different multivariate analyses, using
survival and one other variable stated in the table, showed that the microRNA
profile and KPS were independently associated with survival (although only
KPS was significant after multiple testing correction (p=0.042)). IDH1 refers to
IDH1 mutation status.
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